Study identifier:D1690R00007
ClinicalTrials.gov identifier:NCT02695121
EudraCT identifier:N/A
CTIS identifier:N/A
Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments
Breast Cancer
N/A
No
-
All
1125000
Observational
N/A
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|